Note: Descriptions are shown in the official language in which they were submitted.
CA 02478881 2004-09-09
WO 03/078649 PCT/US03/07641
METHODS TO INCREASE NUCLEOTIDE SIGNALS BY RAMAN
SCATTERING
FIELD OF THE INVENTION
(0001] The present methods and apparatus relate to the fields of molecular
biology and
genomics. More particularly, the methods and apparatus concern nucleic acid
sequencing.
BACKGROUND
[0002] Genetic information is stored in the form of very long molecules of
deoxyribonucleic acid (DNA), organized into chromosomes. The human genome
contains
approximately three billion bases of DNA sequence. This DNA sequence
information
determines multiple characteristics of each individual. Many common diseases
are based
at least in part on variations in DNA sequence.
[0003] Determination of the entire sequence of the human genome has provided a
foundation for identifying the genetic basis of such diseases. However, a
great deal of
work remains to be done to identify the genetic variations associated with
each disease.
That would require DNA sequencing of portions of chromosomes in individuals or
families exhibiting each such disease, in order to identify specific changes
in DNA
sequence that promote the disease.' Ribonucleic acid (RNA), an intermediary
molecule in
processing genetic i nformation, m ay also b a s equenced t o i dentify t he
genetic b aces o f
various diseases.
(0004] Existing methods for nucleic acid sequencing, based on detection of
fluorescently 1 abeled n ucleic a cids t hat h ave b een s eparated b y s ize,
a re 1 united b y t he
length of the nucleic acid that can be sequenced. Typically, only 500 to 1,000
bases of
nucleic acid sequence can be determined at one time. This is much shorter than
the length
of the functional unit of DNA, referred to as a gene, which can be tens or
even hundreds of
thousands of bases in length. Using current methods, determination of a
complete gene
sequence requires that many copies of the gene be produced, cut into
overlapping
fragments and sequenced, after which the overlapping DNA sequences may be
assembled
into the complete gene. This process is laborious, expensive, inefficient and
time-
consuming.
1
CA 02478881 2004-09-09
WO 03/078649 PCT/US03/07641
BRIEF DESCRIPTION OF THE DRAWINGS
[0005] The following drawings form part of the present specification and are
included
to further demonstrate certain aspects of the disclosed embodiments of the
invention. The
embodiments of the invention may be better understood by reference to one or
more of
these drawings in combination with the detailed description of specific
embodiments of
the invention presented herein.
[0006] FIG. 1 illustrates an exemplary apparatus 10 (not to scale) and method
for
nucleic acid 13 sequencing, using nucleotides 16 covalently attached to Raman
labels.
[0007] FIG. 2 illustrates an exemplary apparatus 100 (not to scale) and method
for
nucleic acid 13 sequencing in which the released nucleotides 130 are
covalently attached
to nanoparticles 140 prior to detection by surface enhance Raman spectroscopy
(SERS)
180.
[0008] FIG. 3 illustrates another exemplary apparatus 210 (not to scale) for
nucleic acid
13 sequencing.
DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS
[0009] The disclosed methods and apparatus are of use for the rapid, automated
sequencing of nucleic acids 13. In particular embodiments of the invention,
the methods
and apparatus 10, 100, 210 are suitable for obtaining the sequences of very
long nucleic
acid molecules 13 of greater than 1,000, greater than 2,000, greater than
5,000, greater
than 10,000 greater than 20,000, greater than 50,000, greater than 100,000 or
even more
bases in length. Advantages over prior art methods include the ability to read
long nucleic
acid 13 sequences in a single sequencing run, greater speed of obtaining
sequence data,
decreased cost of sequencing and greater efficiency in operator time required
per unit of
sequence data.
[0010] In various embodiments of the invention, sequence information may be
obtained
during the course of a single sequencing run, using a single nucleic acid
molecule 13. In
other embodiments of the invention, multiple copies of a nucleic acid molecule
13 may be
sequenced in parallel or sequentially to confirm the nucleic acid sequence or
to obtain
complete s equence d ata. In a lternative a mbodiments o f t he i nvention,
both t he n ucleic
2
CA 02478881 2004-09-09
WO 03/078649 PCT/US03/07641
acid molecule 13 and its complementary strand may be sequenced to confirm the
accuracy
of the sequence information.
[0011] In certain embodiments of the invention, the nucleic acid 13 to be
sequenced is
DNA, although it is contemplated that other nucleic acids 13 comprising RNA or
synthetic
nucleotide analogs could be sequenced as well. The following detailed
description
contains numerous specific details in order to provide a more thorough
understanding of
the disclosed embodiments of the invention. However, it will be apparent to
those skilled
in the art that the embodiments of the invention may be practiced without
these specific
details. In other instances, devices, methods, procedures, and individual
components that
are well known in the art have not been described in detail herein.
[0012] In various embodiments of the invention, exemplified in FIG. 1,
nucleotides may
be covalently attached to Raman labels to enhance the Raman signal detected by
surface
enhanced Raman spectroscopy (SERS), surface enhanced resonance Raman
spectroscopy
(SERRS), coherent anti-Stokes Raman spectroscopy (CARS) or other known Raman
detection techniques. In some embodiments of the invention, such labeled
nucleotides
may be incorporated into a newly synthesized nucleic acid strand 13 using
standard
nucleic acid polymerization techniques. Typically, either a primer of specific
sequence or
one or more r andom primers is allowed to hybridize to a template nucleic
acid. Upon
addition of a polymerase and labeled nucleotides, the Raman labeled
nucleotides are
covalently attached to the 3' end of the primer, resulting in the formation of
a labeled
nucleic acid strand 13 complementary in sequence to the template.
[0013] After synthesis, the labeled nucleic acid strand 13 may be digested
with one or
more exonucleases 15. The skilled artisan will realize that the disclosed
methods are not
limited to exonucleases 15 per se, but may utilize any enzyme or other reagent
capable of
sequentially removing nucleotides 16, 130 from at least one end of a nucleic
acid 13. In
certain embodiments of the invention, Raman labeled nucleotides 16, 130 are
sequentially
released from the 3' end 17 of the labeled nucleic acid 13. After separation
from the
labeled nucleic acid 13, the Raman labeled nucleotides 16, 130 are detected by
a detection
unit 18, 180, 300. Information on sequentially detected labeled nucleotides
16, 130 is
used to compile a sequence of the labeled nucleic acid 13, which is
complementary to the
sequence of the template strand.
3
CA 02478881 2004-09-09
WO 03/078649 PCT/US03/07641
[0014] In some embodiments of the invention, the labeled nucleic acid strand
13 may be
separated from the unlabeled template strand as well as unincorporated
nucleotides prior
to exonuclease 15 treatment. This may be accomplished, for example, by using a
primer
that has been cross-linked to a surface 14 or that contains biotin or a
similar group that
may be attached to a surface 14. Biotin labeled primers may be attached to a
surface 14
that has been covalently modified with avidin or streptavidin. The labeled
nucleic acid 13
may be separated from the unlabeled template strand by known techniques.
[0015] In certain a mbodiments of t he i nvention, a ach o f t he f our t ypes
o f n ucleotide
may be attached to a distinguishable Raman label. In other embodiments of the
invention,
only the purine nucleotides (cytosine and/or thymine andlor uracil) may be
labeled. In one
exemplary embodiment, the labeled nucleotides may comprise biotin-labeled
deoxycytidine-5'-triphosphate (biotin-dCTP) and digoxigenin-labeled
deoxyuridine-5'-
triphosphate (digoxigenin-dUTP).
[0016] In alternative embodiments of the invention, exemplified in FIG. 2, the
Raman
signal may be enhanced by covalent attachment of nucleotides 16, 130 to
nanoparticles
140. In certain embodiments of the invention, such attachment would follow
exonuclease
15 treatment of a nucleic acid 13 as disclosed in FIG. 1. In some embodiments
of the
invention, the nanoparticles 140 are silver or gold, but other types of
nanopaxticles 140
known to provide surface enhanced Raman signals are contemplated. The
nanoparticles
140 may either be single nanoparticles 140, aggregates of nanoparticles 140,
or some
mixture of single and aggregated nanoparticles 140. In certain embodiments of
the
invention, a linker compound may be used to attach the nucleotides 16, 130 to
the
nanoparticles 140. In various embodiments of the invention, the linker
compound may be
between 1 to 100 nanometers (nm), 2 to 90 nm, 3 to 80 nm, 4 to 70 nm, 5 to 60
nm, 10 to
50 nm, 15 to 40 nm or 20 to 30 nm in length. In certain embodiments of the
invention, the
linker compound may be between 1 to 50, 1 to 5, 2 to 10, 10 to 20 nm or about
5 nm in
length. In other embodiments of the invention, two or more nanoparticles 140
may be
attached together using linker compounds.
[0017] Following covalent attachment, the nanoparticle-nucleotide complexes
150 may
pass through a flow-through cell 170, 290 where they are detected by SERS,
SERRS
and/or CARS using a detection unit 18, 180, 300. In some alternative
embodiments of the
4
CA 02478881 2004-09-09
WO 03/078649 PCT/US03/07641
invention, the nucleotides 16, 130 may be unmodified, while in other
alternative
embodiments the nucleotides 16, 130 may be modified with one or more Raman
labels. In
certain embodiments of the invention, each type of nucleotide 16, 130 may be
attached to
a distinguishable Raman label. In other embodiments only pyrimidines 16, 130
may be
labeled.
Definitions
[0018] As used herein, "a" or "an" may mean one or more than one of an item.
[0019] As used herein, "operably coupled" means that there is a functional
interaction
between two or more units. For example, a detector 21, 310 may be "operably
coupled" to
a flow-through cell 170, 290 if the detector 21, 310 is arranged so that it
may detect
analytes, such as nucleotides 16, 130, as they pass through the flow-through
cell 170, 290.
[0020] °'Nucleic acid" 13 encompasses DNA, RNA, single-stranded, double-
stranded or
triple stranded and any chemical modifications thereof. Virtually any
modification of the
nucleic acid 13 is contemplated. As used herein, a single stranded nucleic
acid 13 may be
denoted by the prefix "ss", a double stranded nucleic acid 13 by the prefix
"ds", and a
triple stranded nucleic acid 13 by the prefix "ts."
[0021] A "nucleic acid" 13 may be of almost any length, from 10, 20, 30, 40,
50, 60, 75,
100, 150, 200, 250, 300, 400, 500, 600, 700, 800, 900, 1000, 1500, 2000, 2500,
3000,
3500, 4000, 4500, 5000, 6000, 7000, 8000, 9000, 10,000, 15,000, 20,000,
30,000, 40,000,
50,000, 75,000, 100,000, 150,000, 200,000, 500,000, 1,000,000, 1,500,000,
2,000,000,
5,000,000 or even more bases in length, up to a full-length chromosomal DNA
molecule
13.
[0022] A '°nucleoside" 16, 130 i s a molecule comprising a purine or
pyrimidine base
(adenine - "A", cytosine - "C", guanine - "G", thymine - "T" or uracil - "LT")
or any
chemical modification or structural analog thereof, covalently attached to a
pentose sugar
such as deoxyribose, ribose or derivatives or analogs of pentose sugars.
[0023] A "nucleotide" 16, 130 refers to a nucleoside 16, 130 further
comprising at least
one phosphate group covalently attached to the pentose sugar. In some
embodiments of
the invention, the nucleotides 16, 130 are ribonucleoside monophosphates 16,
130 or
deoxyribonucleoside monophosphates 16, 130, although it is anticipated that
nucleoside
5
CA 02478881 2004-09-09
WO 03/078649 PCT/US03/07641
diphosphates or triphosphates 16, 130 could be produced and detected. In other
embodiments of the invention, nucleosides 16, 130 may be released from the
nucleic acid
molecule 13. It is contemplated that various substitutions or modifications
may be made
in the structure of the nucleotides 16, 130, so long as they are capable of
being
incorporated into a nucleic acid 13 by polymerase activity and released by an
exonuclease
or equivalent reagent. In embodiments of the invention involving one or more
labels
attached to one or more types of nucleotide 16, 130, the label may be attached
to any
portion of the nucleotide 16, 130, such as the base, the sugar or the
phosphate groups or
their analogs, so long as the label does not interfere with the polymerization
and/or
10 digestion of a nucleic acid 13. The terms "nucleotide" and "labeled
nucleotide"
encompass, but are not limited to, all non-naturally nucleotide complexes,
such as
nucleotide-nanoparticle complexes and nucleotide-label complexes.
[0024] A "Raman label" may be any organic or inorganic molecule, atom, complex
or
structure capable of producing a detectable Raman signal, including but not
limited to
15 synthetic molecules, dyes, naturally occurring pigments such as
phycoerythrin, organic
nanostructures such as C60, buckyballs and carbon nanotubes, metal
nanostructures such
as gold or silver nanoparticles or nanoprisms and nano-scale semiconductors
such as
quantum d ots. N umerous a xamples o f R aman 1 abels a re d isclosed b elow.
T he s killed
artisan will realize that such examples are not limiting, and that "Raman
label"
encompasses any organic or inorganic atom, molecule, compound or structure
known in
the art that can be detected by Raman spectroscopy.
Nucleic Acids
[0025] Nucleic acid molecules 13 to be sequenced may be prepared by any
technique
known in the art. In certain embodiments of the invention, the nucleic acids
13 are
naturally occurring DNA or RNA molecules. V irtually any.n aturally o ccurring
nucleic
acid 13 may be prepared and sequenced by the disclosed methods including,
without limit,
chromosomal, mitochondrial and chloroplast DNA and ribosomal, transfer,
heterogeneous
nuclear and messenger RNA (mRNA). Methods for preparing and isolating various
forms
of nucleic acids 13 are lcnown. (See, e.g., Guide to Molecular Cloning
Techniques, eds.
Berger and I~immel, Academic Press, New York, NY, 197; Molecular Cloning: A
Laboratory Manual, 2nd Ed., eds. Sambrook, Fritsch and Maniatis, Cold Spring
Harbor
6
CA 02478881 2004-09-09
WO 03/078649 PCT/US03/07641
Press, Cold Spring Harbor, NY, 1989). The methods disclosed in the cited
references are
exemplary only and any variation known in the art may be used. In cases where
single
stranded DNA (ssDNA) 13 is to be sequenced, an ssDNA 13 may be prepared from
double stranded DNA (dsDNA) by any known method. Such methods may involve
heating dsDNA and allowing the strands to separate, or may alternatively
involve
preparation of ssDNA 13 from dsDNA by known amplification or replication
methods,
such as cloning into M13. Any such known method may be used to prepare ssDNA
or
ssRNA 13.
[0026] Although certain embodiments of the invention concern preparation of
naturally
occurnng nucleic acids 13, virtually any type of nucleic acid 13 that can
serve as a
substrate for an exonuclease or equivalent reagent 15 could potentially be
sequenced. For
example, nucleic acids 13 prepared by various amplification techniques, such
as
polymerase chain reaction (PCRTM) amplification, could be sequenced. (See U.S.
Patent
Nos. 4,683,195, 4,683,202 and 4,800,159.) Nucleic acids 13 to be sequenced may
alternatively be cloned in standard vectors, such as plasmids, cosmids, BACs
(bacterial
artificial chromosomes) or YACs (yeast artificial chromosomes). (See, e.g.,
Berger and
Kimmel, 1987; Sambroolc et al., 1989.) Nucleic acid inserts 13 may be isolated
from vector
DNA, for example, by excision with appropriate restriction endonucleases,
followed by
agarose gel electrophoresis. Methods for isolation of insert nucleic acids 13
are well known.
Isolation of Single Nucleic Acid Molecules
[0027] In certain embodiments of the invention, the nucleic acid molecule 13
to be
sequenced is a single molecule of ssDNA or ssRNA. A variety of methods for
selection
and manipulation of single nucleic acid molecules 13 may be used, for example,
hydrodynamic focusing, micro-manipulator coupling, optical trapping, or a
combination of
these and similar methods. (See, e.g., Goodwin et al., 1996, Aec. Chem. Res.
29:607-619;
U.S. PatentNos. 4,962,037; 5,405,747; 5,776,674; 6,136,543; 6,225,068.)
[0028] In certain embodiments of the invention, microfluidics or nanofluidics
may be
used to sort and isolate nucleic acid molecules 13. Hydrodynamics may be used
to
manipulate the movement of nucleic acids 13 into a microchannel,
microcapillary, or a
micropore. In o ne a mbodiment o f t he i nvention, h ydrodynamic forces may b
a a sed t o
move nucleic acid molecules 13 across a comb structure to separate single
nucleic acid
7
CA 02478881 2004-09-09
WO 03/078649 PCT/US03/07641
molecules 13. Once the nucleic acid molecules 13 have been separated,
hydrodynamic
focusing may be used to position the molecules 13 within a reaction chamber
11, 220. A
thermal or electric potential, pressure or vacuum can also be used to p rovide
a motive
force for manipulation of nucleic acids 13. In exemplary embodiments of the
invention,
manipulation of nucleic acids 13 for sequencing may involve the use of a
channel bloclc
design incorporating microfabricated channels and an integrated gel material
(see U.S.
Patent Nos. 5,867,266 and 6,214,246).
[0029] In another embodiment o f the invention, a sample containing the
nucleic acid
molecule 13 may be diluted prior to coupling to an immobilization surface 14.
In
exemplary embodiments o f t he i nvention, t he i mmobilization s urface 14 m
ay b a i n t he
form of magnetic or non-magnetic beads or other discrete structural units. At
an
appropriate dilution, each bead 14 will have a statistical probability of
binding zero or one
nucleic acid molecule 13. Beads 14 with one attached nucleic acid molecule 13
may be
identified using, for example, fluorescent dyes and flow cytometer sorting or
magnetic
sorting. Depending on the relative sizes and uniformity of the beads 14 and
the nucleic
acids 13, it may be possible to use a magnetic filter and mass separation to
separate beads
14 containing a single bound nucleic acid molecule 13. In other embodiments of
the
invention, multiple nucleic acids 13 attached to a single bead or other
immobilization
surface 14 may be sequenced.
[0030] In alternative embodiments of the invention, a coated fiber tip 14 may
be used to
generate single molecule nucleic acids 13 for sequencing (e.g., U.S. Patent
No. 6,225,068).
In other alternative embodiments, the immobilization surfaces 14 may be
prepared to
contain a single molecule of avidin or other cross-linking agent. Such a
surface 14 could
attach a single biotinylated nucleic acid molecule 13 to be sequenced. This
embodiment is
not limited to the avidin-biotin binding system, but may be adapted to any
known coupling
system.
[0031] In other alternative embodiments of the invention, an optical trap may
be used
for manipulation of single molecule nucleic acid molecules 13 for sequencing.
(E.g., U.S.
Patent No. 5,776,674). E xemplary optical trapping systems are commercially
available
from Cell Robotics, Inc. (Albuquerque, NM), S+L GmbH (Heidelberg, Germany) and
P.A.L.M. Gmbh (Wolfratshausen, Germany).
s
CA 02478881 2004-09-09
WO 03/078649 PCT/US03/07641
Raman Labels
[0032] Certain embodiments of the invention may involve attaching a label to
the
nucleotides 16, 130 to facilitate their measurement by the detection unit 18,
180, 300.
Non-limiting examples of labels that could be used for Raman spectroscopy
include TRIT
(tetramethyl rhodamine isothiol), NBD (7-nitrobenz-2-oxa-1,3-diazole), Texas
Red dye,
phthalic acid, terephthalic acid, isophthalic acid, cresyl fast violet, cresyl
blue violet,
brilliant cresyl blue, para-aminobenzoic acid, erythrosine, biotin,
digoxigenin, 5-carboxy-
4',5'-dichloro-2',7'-dimethoxy fluorescein, 5-carboxy-2',4',5',7'-
tetrachlorofluorescein, 5-
carboxyfluorescein, 5-carboxy rhodamine, 6-carboxyrhodamine, 6-
carboxytetramethyl
amino phthalocyanines, azomethines, cyanines, xanthines, succinylfluoresceins
and
aminoacridine. These and other Raman labels may be obtained from commercial
sources
(e.g., Molecular Probes, Eugene, OR).
[0033] Polycyclic aromatic compounds may function as Raman labels, as is known
in
the art. Other labels that may be of use for particular embodiments of the
invention
include cyanide, thiol, chlorine, bromine, methyl, phosphorus and sulfur. In
certain
embodiments of the invention, carbon nanotubes may be of use as Raman labels.
The use
of labels in Raman spectroscopy is known (e.g., U.S. Patent Nos. 5,306,403 and
6,174,677). The skilled artisan will realize that the Raman labels used should
generate
distinguishable Raman spectra and may be specifically bound to or associated
with
different types of nucleotides 16, 130.
[0034] Labels may be attached directly to the nucleotides 16, 130 or may be
attached
via various linker compounds. Cross-linking reagents and linker compounds of
use in the
disclosed methods are further described below. Alternatively, nucleotides that
are
covalently attached to Raman labels are available from standard commercial
sources (e.g.,
Roche Molecular Biochemicals, Indianapolis, IN; Promega Corp., Madison, WI;
Ambion,
Inc., Austin, TX; Amersham Pharmacia Biotech, Piscataway, N~. Raman labels
that
contain reactive groups designed to covalently react with other molecules,
such as
nucleotides 16, 130, are commercially available (e.g., Molecular Probes,
Eugene, OR).
Methods for preparing labeled nucleotides and incorporating them into nucleic
acids 13
are known (e.g., U.S. Patent Nos. 4,962,037; 5,405,747; 6,136,543; 6,210,896).
9
CA 02478881 2004-09-09
WO 03/078649 PCT/US03/07641
Nanoparticles
[0035] Certain embodiments of the invention involve the use of nanoparticles
140 to
enhance the Raman signal obtained from nucleotides 16, 130. In some
embodiments of
the invention, the nanoparticles 140 are silver or gold nanoparticles 140,
although any
nanoparticles 140 capable of providing a surface enhanced Raman spectroscopy
(SERS)
signal may be used. In alternative embodiments of the invention, the
nanoparticles 140
may be nanoprisms (Jin et al., Science 294:1902-3, 2001.) In various
embodiments of the
invention, nanoparticles 140 of between 1 nm and 2 micrometers (~,m) in
diameter may be
used. In alternative embodiments of the invention, nanoparticles 140 of
between 2 nm to 1
~,m, 5 nm to 500 nm, 10 nm to 200 nm, 20 nm to 100 nm, 30 nm to 80 nm, 40 nm
to 70
nm or 50 to 60 nm diameter are contemplated. In certain embodiments of the
invention,
nanoparticles 140 with an average diameter of 10 to SO nm, 50 to 100 nm or
about 100 nm
are contemplated. The nanoparticles 140 may be approximately spherical, rod-
like, edgy,
faceted or pointy in shape, although nanoparticles 140 of any shape or of
irregular shape
may be used. Methods of preparing nanoparticles are known (e.g., U.S. Patent
Nos.
6,054,495; 6,127,120; 6,149,868; Lee and Meisel, J. Phys. Chern. 86:3391-3395,
1982; Jin
et al., 2001). Nanoparticles may also be obtained from commercial sources
(e.g.,
Nanoprobes Inc., Yaphanlc, NY; Polysciences, Inc., Warrington, PA).
[0036] In certain embodiments of the invention, the nanoparticles 140 may be
single
nanoparticles 140 and/or random aggregates of nanoparticles 140 (colloidal
nanoparticles
140). In other embodiments of the invention, nanoparticles 140 may be cross-
linked to
produce particular aggregates of nanoparticles 140, such as dimers, trimers,
tetramers or
other aggregates. Certain alternative embodiments of the invention may use
heterogeneous mixtures of aggregates of different size, while other
alternative
embodiments may use homogenous populations of nanoparticles 140. In certain
embodiments of the invention, aggregates containing a selected number of
nanoparticles
140 (dimers, trimers, etc.) may be enriched or purified by known techniques,
such as
ultracentrifugation in sucrose solutions. In various embodiments of the
invention,
nanoparticle 140 aggregates of about 100, 200, 300, 400, 500, 600, 700, 800,
900 to 1000
nm in size or larger are contemplated.
[0037] Methods of cross-linking nanoparticles 140 are known (e.g., Feldheim,
°"Assembly
of metal nanoparticle arrays using molecular bridges," The Electrochemical
Society
CA 02478881 2004-09-09
WO 03/078649 PCT/US03/07641
Interface, Fall, 2001, pp. 22-25). Gold nanoparticles 140 may be cross-linked,
for
example, using bifunctional linker compounds bearing terminal thiol or
sulfliydryl groups.
Upon reaction with gold nanoparticles 140, the linker forms nanoparticle 140
dimers that
are separated by the length of the linker. In other embodiments of the
invention, linkers
with three, four or more thiol groups may be used to simultaneously attach to
multiple
nanoparticles 140 (Feldheim, 2001). The use of an excess of nanoparticles 140
to linker
compounds prevents formation of multiple cross-linlcs and nanoparticle 140
precipitation.
Aggregates of silver nanoparticles 140 may be formed by standard synthesis
methods
known in the art.
[0038] In alternative embodiments of the invention, the nanoparticles 140 may
be
modified to contain various reactive groups before they are attached to linker
compounds.
Modified nanoparticles 140 are commercially available, such as Nanogold~
nanoparticles
140 from Nanoprobes, Inc. (Yaphanle, NY). Nanogold~ nanoparticles 140 may be
obtained with either single or multiple maleimide, amine or other groups
attached per
nanoparticle 140. The Nanogold~ nanoparticles 140 are also available in either
positively
or negatively charged form. Such modified nanoparticles 140 may be attached to
a variety
of known linker compounds to provide dimers, trimers or other aggregates of
nanoparticles 140.
[0039] The type of linker compound used is not limiting, so long as it results
in the
production of small aggregates of nanoparticles 140 that will not precipitate
in solution. In
some embodiments of the invention, the linlcer group may comprise
phenylacetylene
polymers (Feldheim, 2001). Alternatively, linker groups may comprise
polytetrafluoroethylene, polyvinyl pyrrolidone, polystyrene, polypropylene,
polyacrylamide, polyethylene or other known polymers. The linker compounds of
use are
not limited to polymers, but may also include other types of molecules such as
silanes,
alkanes, derivatized silanes or derivatized alkanes.
[0040] In various embodiments of the invention, the nanoparticles 140 may be
covalently
attached to nucleotides 16, 130. In alternative embodiments of the invention,
the
nucleotides 16, 130 may be directly attached to the nanoparticles 140, or may
be attached
to linker compounds that are covalently or non-covalently bonded to the
nanoparticles
140. In such embodiments of the invention, rather than cross-linking two or
more
nanoparticles 140 together the linker compounds may be used to attach a
nucleotide 16,
11
CA 02478881 2004-09-09
WO 03/078649 PCT/US03/07641
130 to a nanoparticle 140 or a nanoparticle 140 aggregate. In particular
embodiments of
the invention, the nanoparticles 140 may be coated with derivatized silanes.
Such
modified silanes may be covalently attached to nucleotides 16, 130 using
standard
methods. Various methods known for cross-linking nucleic acids 13 to surfaces
14
discussed below may also be used to attach nucleotides 16, 130 to
nanoparticles 140. It is
contemplated that the linker compounds used to attach nucleotides 16, 130 may
be of
almost any length, ranging from about 0.05, 0.1, 0.2, 0.5, 0.75, 1, 2, 3, 4,
5, 6, 7, 8, 9, 10,
11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 27, 30, 35, 40,
45, 50, 55, 60, 65,
60, 80, 90 to 100 nm or even greater length. Certain embodiments of the
invention may
use linkers of heterogeneous length.
[0041] In other embodiments of the invention, nucleotides 16, 130 may be
adsorbed on the
surface o f t he n anoparticles 140 o r m ay b a i n c lose p roximity t o t
he n anoparticles 140
(between about 0.2 and 1.0 nm). The skilled artisan will realize that it
covalent attachment
of the nucleotides 16, 130 to nanoparticles 140 is not required in order to
generate an
enhanced Raman signal by SERS, SERRS or CARS.
[0042] In the exemplary embodiment of the invention disclosed in FIG. 2, the
nucleotides
130 are attached to nanoparticles 140 as they travel down a microfluidic
channel 160 to
form nucleotide-nanoparticle complexes 150. In certain embodiments of the
invention, the
length of time available for the cross-linking reaction to occur may be very
limited. Such
embodiments m ay a tilize h ighly r eactive c ross-linking g roups w ith r
apid r eaction r ates,
such as epoxide groups, azido groups, arylazido groups, triazine groups or
diazo groups.
In certain embodiments of the invention, the cross-linking groups may be
photoactivated
by exposure to intense light, such as a laser. For example, photoactivation of
diazo or
azido compounds results in the formation, respectively, of highly reactive
carbene and
nitrene m oieties. In certain a mbodiments o f t he i nvention, t he r eactive
groups m ay be
selected so that they can only attach the nanoparticles 140 to nucleotides 16,
130, rather
than cross-linking the nanoparticles 140 to each other. The selection and
preparation of
reactive cross-linking groups capable of binding to nucleotides 16, 130 is
known in the art.
In alternative embodiments of the invention, nucleotides 16, 130 may
themselves be
covalently modified, for example with a sulfhydryl group that can attach to
gold
nanoparticles 140.
12
CA 02478881 2004-09-09
WO 03/078649 PCT/US03/07641
[0043] In c ertain a mbodiments o f t he i nvention, n anoparticles 140 m ay b
a m anipulated
into microfluidic channels 120, 160, 270, 280 by any method lcnown in the art,
such as
microfluidics, nanofluidics, hydrodynamic focusing or electro-osmosis. In some
embodiments of the invention, use of charged linker compounds or charged
nanoparticles
140 may facilitate manipulation of nanoparticles 140 through the use of
electrical
gradients.
Immobilization of Nucleic Acids
[0044] In certain embodiments of the invention, as exemplified in FIG. l, one
or more
nucleic acid molecules 13 may be attached to a surface 14 such as
functionalized glass,
silicon, silicate, PDMS (polydimethyl siloxane), polyvinylidene difluoride
(PVDF), silver
or other metal coated surfaces, quartz, plastic, PTFE
(polytetrafluoroethylene), PVP
(polyvinyl pyrrolidone), polyvinyl chloride), poly(methyl methacrylate),
poly(dimethyl
siloxane), polystyrene, polypropylene, polyacrylamide, latex, nylon,
nitrocellulose, glass
beads, magnetic beads, photopolymers which contain photoreactive species such
as
nitrenes, carbenes and ketyl radicals capable of forming covalent links with
nucleic acid
molecules 13 (See U.S. Pat. Nos. 5,405,766 and 5,986,076) or any other
material known in
the art that is capable of having functional groups such as amino, carboxyl,
thiol, hydroxyl
or Diels-Alder reactants incorporated on its surface 14.
[0045] In some embodiments of the invention, the surface functional groups may
be
covalently attached to cross-linking compounds so that binding interactions
between
nucleic acid molecule 13 and exonuclease 15 and/or polymerise may occur
without steric
hindrance. Typical cross-linking groups include ethylene glycol oligomers and
diamines.
Attachment may be by either covalent or non-covalent binding. Various methods
of
attaching nucleic acid molecules 13 to surfaces 14 are known in the art and
may be
employed. In certain embodiments of the invention, the nucleic acid molecule
13 is fixed
in place and immersed in a microfluidic flow down a flow path 12 and/or
microfluidic
channel 110, 160, 260, 280 that transports the released nucleotides 16, 130
past a detection
unit 18, 180, 300. In non-limiting examples, the microfluidic flow may result
from a bulk
flow of solvent down a flow path 12 and/or microfluidic channel 110, 160, 260,
280.
[0046] In alternative embodiments of the invention, the bulk medium moves only
slowly or not at all, but charged species within the solution (such as
negatively charged
13
CA 02478881 2004-09-09
WO 03/078649 PCT/US03/07641
nucleotides 16, 130) m ove d own a f low p ath 12 a nd/or m icrofluidic c
hannel 1 10, 160,
260, 280 in response to an externally applied electrical field.
[0047] Immobilization of nucleic acid molecules 13 may b a achieved by a
variety of
known methods. In an exemplary embodiment of the invention, immobilization may
be
achieved by coating a surface 14 with streptavidin or avidin and the
subsequent attachment
of a biotinylated nucleic acid 13 (Holmstrom et al., Anal. Biochem. 209:278-
283, 1993).
Immobilization may also occur by coating a silicon, glass or other surface 14
with poly-L-
Lys (lysine) or poly L-Lys, Phe (phenylalanine), followed by covalent
attachment of either
amino- or sulfhydryl-modified nucleic acids 13 a sing bifunctional
crosslinking reagents
(Running et al., BioTeclaniques 8:276-277, 1990; Newton et al., Nucleic Acids
Res.
21:1155-62, 1993). Amine residues may b a c oated on a surface 14 through the
use of
aminosilane.
[0048] Immobilization may take place by direct covalent attachment of 5'-
phosphorylated n ucleic acids 13 t o chemically modified s urfaces 14 (
Rasmussen a t a l.,
Anal. Biochern. 198:138-142, 1991). The covalent bond between the nucleic acid
13 and
the surface 14 may be formed by condensation with a water-soluble
carbodiimide. This
method facilitates a predominantly 5'-attachment of the nucleic acids 13 via
their 5'-
phosphates.
[0049] DNA 13 is commonly bound to glass by first silanizing the glass surface
14, then
activating with carbodiimide or glutaraldehyde. Alternative procedures may use
reagents
such as 3-glycidoxypropyltrimethoxysilane (GOP) or aminopropyltrimethoxysilane
(APTS) with DNA 13 linked via amino linkers incorporated at either the 3' or
5' end of the
molecule. DNA 13 may be bound directly to membrane surfaces 14 using
ultraviolet
radiation. Other non-limiting examples of immobilization techniques for
nucleic acids 13
are disclosed in U.S. Paterit Nos. 5,610,287, 5,776,674 and 6,225,068.
[0050] Bifunctional cross-linking reagents may be of use in various
embodiments of the
invention, such as attaching a nucleic acid molecule 13 to a surface 14. The
bifunctional
cross-linking reagents can be divided according to the specificity of their
functional
groups, e.g., amino, guanidino, indole, or carboxyl specific groups. Exemplary
methods
for c ross-linking m olecules a re d isclosed i n U .S. P atent N os. 5
,603,872 and 5 ,401,511.
Cross-linking reagents include glutaraldehyde (GAD), bifunctional oxirane
(OXR),
14
CA 02478881 2004-09-09
WO 03/078649 PCT/US03/07641
ethylene glycol diglycidyl ether (EGDE), and carbodiimides, such as 1-ethyl-3-
(3-
dimethylaminopropyl) carbodiimide (EDC).
Nucleic Acid Synthesis
Polymerises
[0051] Certain embodiments of the invention involve binding of a synthetic
reagent, such
as a DNA polymerise, to a primer molecule and the addition of Raman labeled
nucleotides
to the 3' end of the primer. Non-limiting examples of polymerises include DNA
polymerises, RNA polymerises, reverse transcriptases, and RNA-dependent RNA
polymerises. The differences between these polymerises in terms of their
"proofreading"
activity and requirement or lack of requirement for primers and promoter
sequences are
known in the art. Where RNA polymerises are used as the polymerise, a template
molecule to be sequenced may be double-stranded l~NA. Non-limiting examples of
polymerises include Thernaatoga maritima DNA polymerise, AmplitaqFSTM DNA
polymerise, TaquenaseTM DNA polymerise, ThermoSequenaseTM, Taq DNA polymerise,
QbetaTM replicase, T4 DNA polymerise, Thermus the~mophilus DNA polymerise, RNA-
dependent RNA polymerise and SP6 RNA polymerise.
[0052] A number of polymerises are commercially available, including Pwo DNA
Polymerise (Boehringer Mannheim Biochemicals, Indianapolis, IN); Bst
Polymerise
(Bio-Rad Laboratories, Hercules, CA); IsoThermTM DNA Polymerise (Epicentre
Technologies, Madison, WI); Moloney Murine Leukemia Virus Reverse
Transcriptase,
Pfu DNA Polymerise, Avian Myeloblastosis Virus Reverse Transcriptase, The~mus
flavus
(Tfl) DNA Polymerise and Thermococcus lito~alis (Tli) DNA Polymerise (Promega
Corp., Madison, WI); RAV2 Reverse Transcriptase, HIV-1 Reverse Transcriptase,
T7
RNA Polymerise, T3 RNA Polymerise, SP6 RNA Polymerise, E. cola RNA Polymerise,
Tlaermus aquaticus DNA Polymerise, T7 DNA Polymerise +/- 3'-~5' exonuclease,
Klenow Fragment of DNA Polymerise I, Thermus 'ubiquitous' DNA Polymerise, and
DNA polymerise I (Amersham Pharmacia Biotech, Piscataway, N~. Any polymerise
known in the art capable of template dependent polymerization of labeled
nucleotides may
be used. (See, e.g., Goodman and Tippin, Nat. Rev. Mol. Cell Biol. 1(2):101-9,
2000;
LT.S. Patent No. 6,090,SS9.) Methods of using polymerises to synthesize
nucleic acids 13
CA 02478881 2004-09-09
WO 03/078649 PCT/US03/07641
from labeled nucleotides are known (e.g., U.S. Patent Nos. 4,962,037;
5,405,747;
6,136,543; 6,210,896).
Primes
[0053] Generally, primers are between ten and twenty bases in length, although
longer
primers may be employed. In certain embodiments of the invention, primers are
designed
to be complementary in sequence to a known portion of a template nucleic acid
molecule.
Known primer sequences may be used, for example, where primers are selected
for
identifying sequence variants adjacent to known constant chromosomal
sequences, where
an unknown nucleic acid sequence is inserted into a vector of known sequence,
or where a
native nucleic acid has been partially sequenced. Methods for synthesis of
primers of any
sequence are known. Other embodiments of the invention involve sequencing a
nucleic
acid 13 in the absence of a known primer-binding site. In such cases, it may
be possible to
use random primers, such as random hexamers or random oligomers to initiate
polymerization.
Nucleic Acid Digestion
[0054] In certain embodiments of the invention, exemplified in FIG. 1, methods
of nucleic
acid 13 sequencing involve binding of an exonuclease 15 or equivalent reagent
to the free
end 17 of a nucleic acid molecule 13 and removal of nucleotides 16, 130 one at
a time.
Non-limiting examples of nucleic acid digesting enzymes 15 of potential use
include E.
coli exonuclease I, III, V or VII, Bal 31 exonuclease, mung bean nuclease, S1
nuclease, E.
coli DNA polymerise I holoenzyme or Klenow fragment, RecJ, exonuclease T, T4
or T7
DNA polymerise, Taq polymerise, exonuclease T7 gene 6, snake venom
phosphodiesterase, spleen phosphodiesterase, Them~coccus litoralis DNA
polymerise,
Py~ococcus sp. GB-D DNA polymerise, lambda exonuclease, S aureus micrococcal
nuclease, DNase I, ribonuclease A, T1 micrococcal nuclease, or other
exonucleases known
in the art. Exonucleases 15 are available from commercial sources such as New
England
Biolabs (Beverly, MA), Amersham Pharmacia Biotech (Piscataway, NJ), Promega
(Madison, WI), Sigma Chemicals (St. Louis, MO) or Boehringer Mamiheim
(Indianapolis,
IN).
[0055] The skilled artisan will realize that enzymes with exonuclease 15
activity may
remove nucleotides 16, 130 from the 5' end, the 3' end, or either end of
nucleic acid
16
CA 02478881 2004-09-09
WO 03/078649 PCT/US03/07641
molecules 13. They can show specificity for RNA, DNA or both RNA and DNA 13.
Their activity may depend on the use of either single or double-stranded
nucleic acids 13.
They may be differentially affected by salt concentration, temperature, pH, or
divalent
cations. These end other properties of exonucleases 15 are known in the art.
In certain
embodiments of the invention, the rate of exonuclease 15 activity may be
manipulated to
coincide with the optimal rate of analysis of nucleotides 16, 130 by the
detection unit 18,
180, 300. Various methods are known for adjusting the rate of exonuclease 15
activity,
including adjusting the temperature, pressure, pH, salt or divalent cation
concentration in a
reaction chamber 1 l, 220.
[0056] Although nucleoside monophosphates 16, 130 will generally be released
from
nucleic acids 13 by exonuclease 15 activity, the embodiments of the invention
are not
limited to detection of any particular form of free nucleotide or nucleoside
16, 130 but
encompass any monomer 16, 130 that may be released from a nucleic acid 13.
Reaction Chamber and Integrated Chip
[0057] As exemplified in FIG. 1, some embodiments of the invention concern
apparatus
10, 100, 210 comprising a reaction chamber 11, 220 designed to contain an
immobilization surface 14, nucleic acid molecule 13, exonuclease 1 S and
nucleotides 16,
130 in an aqueous environment. In some embodiments of the invention, the
reaction
chamber 11, 220 may be temperature controlled, for example by incorporation of
Pelletier
elements or other methods known in the art. Methods of controlling temperature
for low
volume liquids are known. (See, e.g., IJ.S. Patent Nos. 5,038,853, 5,919,622,
6,054,263
and 6,180,372.)
[0058] In certain embodiments of the invention, the reaction chamber 11, 220
and any
associated fluid channels, for example, a flow path 12, microfluidic channels
110, 160,
260, 280 or channels 120, 230, 240, 270, 350, 360 to provide connections to
waste ports,
to a nucleic acid 13 loading port, to a nanoparticle reservoir 370, to a
source of
exonuclease 15 or other fluid compartments are manufactured in a batch
fabrication
process, as known in the fields of computer chip manufacture and/or
microcapillary chip
manufacture. In some embodiments of the invention, the reaction chamber 11,
220 and
other components of the apparatus 10, 100, 210, such as the flow path 12
and/or
microfluidic channels 120, 160, 260, 280 may be manufactured as a single
integrated chip.
17
CA 02478881 2004-09-09
WO 03/078649 PCT/US03/07641
Such a chip may be manufactured by methods known in the art, such as by
photolithography a nd a tching. H owever, t he m anufacturing m ethod i s n of
1 inviting a nd
other methods known in the art may be used, such as laser ablation, injection
molding,
casting, molecular beam epitaxy, dip-pen nanolithograpy, chemical vapor
deposition
(CVD) fabrication, electron beam or focused ion beam technology or imprinting
techniques. Methods for manufacture of nanoelectromechanical systems may be
used for
certain embodiments of the invention. (See, e.g., Craighead, Science 290:1532-
36, 2000.)
Microfabricated chips are commercially available from, e.g., Caliper
Technologies Inc.
(Mountain View, CA) and ACLARA BioSciences Inc. (Mountain View, CA).
[0059] To facilitate detection of nucleotides 16, 130 by the detection unit
18, 180, 300
the material comprising the flow path 12 or flow-through cell 170, 290 may be
selected to
be transparent to electromagnetic radiation at the excitation and emission
frequencies used
for the detection unit 18, 180, 300. Glass, silicon, and any other materials
that are
generally transparent in the wavelengths used for Raman spectroscopy may be
used. In
some embodiments of the invention the surfaces of the flow path 12 or flow-
through cell
170, 290 that are opposite the detection unit 18, 180, 300 may be coated with
silver, gold,
platinum, copper, aluminum or other materials that are relatively opaque to
the detection
unit 18, 180, 300. In that position, the opaque material is available to
enhance the Raman
signal, for example by SERS, while not interfering with the function of the
detection unit
18, 180, 300. Alternatively, the flow path 12 or flow-through cell 170, 290
may contain a
mesh comprising silver, gold, platinum, copper, aluminum or other Raman signal
enhancing metal.
Flow Path and Microfluidic Channels
[0060] In certain embodiments of the invention, the nucleotides 16, 130
released from a
nucleic acid 13 are moved down a flow path 12 and/or microfluidic channels
110, 160,
260, 280 past a detection unit 18, 180, 300. A non-limiting example of
techniques for
transport of nucleotides 16, 130 includes microfluidic techniques. The flow
path 12 and/or
microfluidic channels 110, 160, 260, 280 can comprise a microcapillary (e.g.,
from
ACLARA BioSciences Inc., Mountain View, CA) or a liquid integrated circuit
(e.g.,
Caliper Technologies Inc., Mountain View, CA).
18
CA 02478881 2004-09-09
WO 03/078649 PCT/US03/07641
[0061] In certain embodiments of the invention, the nucleotides 16, 130 to be
detected
move down the flow path 12 and/or microfluidic channels 110, 160, 260, 280 by
bulk flow
of solvent. In other embodiments of the invention, microcapillary
electrophoresis may be
used to transport nucleotides 16, 130 down the flow path 12 and/or
microfluidic channels
110, 160, 260, 280. Microcapillary electrophoresis generally involves the use
of a thin
capillary or channel that may or may not be filled with a particular
separation medium.
Electrophoresis of appropriately charged molecular species, such as negatively
charged
nucleotides 16, 130, occurs in response to an imposed electrical field,
negative on the
reaction chamber 1 l, 220 side of the apparatus 10, 100, 210 and positive on
the detection
unit 18, 180, 3 00 s ide. A lthough a lectrophoresis i s o ften a sed f or s
ize s eparation o f a
mixture of components that are simultaneously added to the microcapillary, it
can also be
used to transport similarly sized nucleotides 16, 130 that are sequentially
released from a
nucleic acid 13. Because the purine nucleotides (A, G) 16, 130 are larger than
the
pyrimidine nucleotides (C, T, U) 16, 130 and would therefore migrate more
slowly, the
length of the flow path 12 and/or microfluidic channels 110, 160, 260, 280 and
the
corresponding transit time past the detection unit 18, 180, 300 may kept to a
minimum to
prevent differential migration from mixing up the order of nucleotides 16, 130
released
from the nucleic acid 13. Alternatively, the medium filling the microcapillary
may be
selected so that the migration rates of purine and pyrimidine nucleotides 16,
130 down the
flow path 12 and/or microfluidic channels 110, 160, 260, 280 are similar or
identical.
Methods of microcapillary electrophoresis have been disclosed, for example, by
Woolley
and Mathies (P~oc. Natl. Acad. Sci. USA 91:11348-352, 1994).
[0062] In certain embodiments of the invention, flow paths 12 and/or
microfluidic
channels 110, 160, 260, 280 may contain aqueous solutions with relatively high
viscosity,
such as glycerol solutions. Such high viscosity solutions may serve to
decrease the flow
rate and increase the reaction time available, for example, for cross-linking
nucleotides 16,
130 to nanoparticles 140.
[0063] Microfabrication of microfluidic devices, including microcapillary
electrophoretic devices has been disclosed in, e.g., Jacobsen et al. (Anal.
Biochem,
209:278-283,1994); Effenhauser et al. (Anal. Chem. 66:2949-2953, 1994);
Harnson et al.
(Science 261:895-897, 1993) and U.S. Patent No. 5,904,824. These methods may
19
CA 02478881 2004-09-09
WO 03/078649 PCT/US03/07641
comprise micromolding techniques with silicon masters made using standard
photolithography or focused ion beam techniques, or photolithographic etching
of micron
scale channels on silica, silicon or other crystalline substrates or chips.
Such techniques
may be readily adapted for use in the disclosed methods and apparatus. In some
embodiments of the invention, the microcapillary may be fabricated from the
same
materials used for fabrication of a reaction chamber 11, 220, using techniques
known in
the art.
Detection Unit
[0064] In various embodiments of the invention, the detection unit 18, 180,
300 is
designed to detect and quantify nucleotides 16, 130 by Raman spectroscopy.
Methods for
detection of nucleotides 16, 130 by Raman spectroscopy are known in the art.
(See, e.g.,
U.S. Patent Nos. 5,306,403; 6,002,471; 6,174,677). Variations on surface
enhanced
Raman spectroscopy (SERS), surface enhanced resonance Raman spectroscopy
(SERRS)
and coherent anti-Stokes Raman spectroscopy (CARS).have been disclosed. The
sensitivity of Raman detection is enhanced by a factor of 106 or more for
molecules
adjacent to roughened metal surfaces, such as silver, gold, platinum, copper
or aluminum
surfaces.
[0065] A non-limiting example of a Raman detection unit 18, 180, 300 is
disclosed in
U.S. Patent No. 6,002,471. An excitation beam 20, 330 is generated by either a
frequency
doubled Nd:YAG laser 19, 320 at 532 nm wavelength or a frequency doubled
Tiaapphire
laser 19, 320 at 365 nm wavelength. Pulsed laser beams 20, 330 or continuous
laser beams
20, 330 may be used. The excitation beam 20, 330 passes through confocal
optics and a
microscope objective, and is focused onto the flow path 12 and/or the flow-
through cell
170, 290. The Raman emission light from the nucleotides 16, 130 is collected
by the
microscope objective and the confocal optics and is coupled to a monochromator
for
spectral dissociation. The confocal optics includes a combination of dichroic
filters, barrier
filters, confocal pinholes, lenses, and mirrors for reducing the background
signal. Standard
full field optics can be used as well as confocal optics. The Raman emission
signal is
detected by a Raman detector 21, 310, comprising an avalanche photodiode
interfaced
with a computer for counting and digitization of the signal.
CA 02478881 2004-09-09
WO 03/078649 PCT/US03/07641
[0066] Another example of a Raman detection unit 18, 180, 300 is disclosed in
U.S.
Patent No. 5,306,403, including a Spex Model 1403 double-grating
spectrophotometer 21,
310 with a gallium-arsenide photomultiplier tube (RCA Model C31034 or Burle
Industries
Model C3103402) operated in the single-photon counting mode. The excitation
source 19,
320 comprises a 514.5 nm line argon-ion laser 19, 320 from SpectraPhysics,
Model 166,
and a 647.1 nm line of a krypton-ion laser 19, 320 (Innova 70, Coherent).
[0067] Alternative a xcitation s ources 19, 3 20 i nclude a n itrogen 1 aser
19, 3 20 (Laser
Science Inc.) at 337 nm and a helium-cadmium laser 19, 320 (Liconox) at 325 nm
(U.S.
Patent No. 6,174,677), a light emitting diode 19, 320, an Nd:YLF laser 19,
320, and/or
various ions lasers 19, 320 and/or dye lasers 19, 320. The excitation beam 20,
330 may be
spectrally purified with a bandpass filter (Corion) and may be focused on the
flow path 12
and/or flow-through cell 170, 290 using a 6X obj ective lens (Newport, Model
L6X). The
objective lens may be used to both excite the nucleotides 16, 130 and to
collect the Raman
signal, by using a holographic beam splitter (Kaiser Optical Systems, Inc.,
Model HB 647-
26N18) to produce a right-angle geometry for the excitation beam 20, 330 and
the emitted
Raman signal. A holographic notch filter (Kaiser Optical Systems, Inc.) may be
used to
reduce Rayleigh scattered radiation. Alternative Raman detectors 21, 310
include an ISA
HR-320 spectrograph equipped with a red-enhanced intensified charge-coupled
device
(RE-ICCD) detection system (Princeton Instruments). Other types of detectors
21, 310
may be used, such as Fourier-transform spectrographs (based on Michaelson
interferometers), charged injection devices, photodiode arrays, InGaAs
detectors, electron-
multiplied CCD, intensified CCD and/or phototransistor arrays.
[0068] Any suitable form or configuration of Raman spectroscopy or related
techniques
knov~nn in the art may be used for detection of nucleotides 16, 130, including
but not
limited to normal Raman scattering, resonance Raman scattering, surface
enhanced Raman
scattering, surface enhanced resonance Raman scattering, coherent anti-Stokes
Raman
spectroscopy (CARS), stimulated Raman scattering, inverse Raman spectroscopy,
stimulated gain Raman spectroscopy, hyper-Raman scattering, molecular optical
laser
examiner (MOLE) or Raman microprobe or Raman microscopy or confocal Raman
microspectrometry, three-dimensional or scanning Raman, Raman saturation
21
CA 02478881 2004-09-09
WO 03/078649 PCT/US03/07641
spectroscopy, t ime r esolved r esonance R aman, Raman d ecoupling
spectroscopy o r U V-
Raman microscopy.
Information Processing and Control System and Data Analysis
[0069] In certain embodiments of the invention, the nucleic acid sequencing
apparatus 10,
100, 210 may comprise an information processing system. The disclosed methods
and
apparatus 10, 100, 210 are not limiting for the type of information processing
system used.
An exemplary information processing system may incorporate a computer
comprising a
bus for communicating information and a processor for processing information.
In one
embodiment of the invention, the processor is selected from the Pentium~
family of
processors, including without limitation the Pentium~ II family, the Pentium~
III family
and the Pentium~ 4 family of processors available from Intel Corp. (Santa
Clara, CA). In
alternative embodiments of the invention, the processor may be a Celeron~, an
Itanium~,
or a Pentium Xeon~ processor (Intel Corp., Santa Clara, CA). In various other
embodiments of the invention, the processor may be based on Intel~
architecture, such as
Intel~ IA-32 or Intel~ IA-64 architecture. Alternatively, other processors may
be used.
The information processing and control system may further comprise any
peripheral
devices known in the art, such as memory, display, keyboard and/or other
devices.
[0070] In particular embodiments of the invention, the detection unit 18, 180,
300 may be
operably coupled to the information processing system. Data from the detection
unit 18,
180, 300 may be processed by the processor and data stored in memory. Data on
emission
profiles for standard nucleotides 16, 130 may also be stored in memory. The
processor
may compare the emission spectra from nucleotides 16, 130 in the flow path 12
and/or
flow-through cell 170, 290 to identify the type o f nucleotide 16, 130
released from the
nucleic acid molecule 13. The memory may also store the sequence of
nucleotides 16, 130
released from the nucleic acid molecule 13. The processor may analyze the data
from the
detection unit 18, 180, 300 to determine the sequence of the nucleic acid 13.
The
information processing system may also perform standard procedures such as
subtraction
of background signals and "base-calling" determination when overlapping
signals are
detected.
[0071] While the disclosed methods may be performed under the control of a
programmed
processor, in alternative embodiments of the invention, the methods may be
fully or
22
CA 02478881 2004-09-09
WO 03/078649 PCT/US03/07641
partially implemented by any programmable or hardcoded logic, such as Field
Programmable Gate Arrays (FPGAs), TTL logic, or Application Specific
Integrated
Circuits (ASICs). Additionally, the disclosed methods may be performed by any
combination of programmed general purpose computer components and/or custom
hardware components.
[0072] Following the data gathering operation, the data will typically be
reported to a data
analysis operation. To facilitate the analysis operation, the data obtained by
the detection
unit 18, 180, 300 will typically be analyzed using a digital computer such as
that described
above. Typically, the computer will be appropriately programmed for receipt
and storage
of the data from the detection unit 18, 180, 300 as well as for analysis and
reporting of the
data gathered.
[0073] In certain embodiments of the invention, custom designed software
packages may
be used to analyze the data obtained from the detection unit 18, 180, 300. In
alternative
embodiments of the invention, data analysis may be performed, using an
information
processing system and publicly available software packages. Non-limiting
examples of
available software for DNA sequence analysis include the PRISMTM DNA
Sequencing
Analysis Software (Applied Biosystems, Foster City, CA), the SequencherTM
package
(Gene Codes, Ann Arbor, MI), and a variety of software packages available
through the
National Biotechnology Information Facility at website
www.nbif.org/links/1.4.1.php.
EXAMPLES
Example 1: Nucleic Acid Sequencing Using Raman Labeled Nucleotides
[0074] Certain embodiments of the invention, exemplified in FIG. 1, involve
sequencing of individual single-stranded nucleic acid molecules 13 that are
attached to an
immobilization surface 14 in a reaction chamber 11, 220 and disassembled in a
deconstruction reaction. In such embodiments of the invention, the reaction
chamber 11,
220 contains one or more exonucleases 15 that sequentially remove one
nucleotide 16, 130
at a time from the unattached end 17 of the nucleic acid molecule 13.
[0075] As the nucleotides 16, 130 are released, they move down a flow path 12
past a
detection unit 18, 180, 300. The detection unit 18, 180, 300 comprises an
excitation
source 19, 320, such as a laser, that emits an excitatory beam 20, 330. The
excitatory
beam 20, 330 interacts with the released nucleotides 16, 130 so that electrons
are excited
23
CA 02478881 2004-09-09
WO 03/078649 PCT/US03/07641
to a higher energy state. The Raman emission spectrum that results from the
return of the
electrons to a lower energy state is detected by a Raman spectroscopic
detector 21, 310,
such as a spectrometer, a monochromator or a charge coupled device (CCD), such
as a
CCD camera.
Preparation of Reaction Chamber and Flow Patla
[0076] Borofloat glass wafers (Precision Glass & Optics, Santa Ana, CA) are
pre-etched
for a short period in concentrated HF (hydrofluoric acid) and cleaned before
deposition of
an amorphous silicon sacrificial layer in a plasma-enhanced chemical vapor
deposition
(PECVD) system (PEII-A, Technics West, San Jose, CA). Wafers are primed with
hexamethyldisilazane (HMDS), spin-coated with photoresist (Shipley 1818,
Marlborough,
MA) a nd s oft-baked. A c ontact m ask a ligner ( Quintet C orp. S an Jo se, C
A) i s a sed t o
expose the photoresist layer with one or m~re mask designs, and the exposed
photoresist
removed using a mixture of Microposit developer concentrate (Shipley) and
water.
Developed wafers are hard-baked and the exposed amorphous silicon removed
using CF4
(carbon t etrafluoride) p lasma i n a P ECVD reactor. W afers are c hemically
a tched with
concentrated HF to produce the reaction chamber 11, 220 and flow path 12. The
remaining photoresist is stripped and the amorphous silicon removed. Using
these
methods, microchannels of about 50 to 100 pm diameter may be prepared. Smaller
diameter channels may be prepared by known methods, such as coating the inside
of the
microchannel to narrow the diameter, or using nanolithography, focused
electron beam,
focused ion beam or focused atom laser techniques.
[0077] Access holes are drilled into the etched wafers with a diamond drill
bit
(Crystalite, Westerville, OH). A finished chip is prepared by thermally
bonding two
complementary etched and drilled plates to each other in a programmable vacuum
furnace
(Centurion VPM, J. M. Ney, Yucaipa, CA). Alternative exemplary methods for
fabrication of a chip incorporating a reaction chamber 11, 220 and flow path
12 are
disclosed in U.S. Patent Nos. 5,867,266 and 6,214,246. In certain embodiments
of the
invention, a nylon filter with a molecular weight cutoff of 2,500 daltons is
inserted
between t he r eaction c hamber 1 1, 2 20 a nd t he f low p ath 12 t o p
revent a xonuclease 15
from leaving the reaction chamber 11, 220.
Nucleic Acid Preparation arid Exonuclease Treatment
24
CA 02478881 2004-09-09
WO 03/078649 PCT/US03/07641
[0078] Human chromosomal DNA is purified according to Sambrook et al. (1989).
Following digestion with Bam H1, the genomic DNA fragments are inserted into
the
multiple cloning site of the pBluescript~ II phagemid vector (Stratagene,
Inc., La Jolla,
CA) and grown up in E. coli. After plating on ampicillin-containing agarose
plates a
single colony is selected and grown up for sequencing. Single-stranded DNA
copies of
the genomic DNA insert are rescued by co-infection with helper phage. After
digestion in
a solution of proteinase Kaodium dodecyl sulphate (SDS), the DNA is phenol
extracted
and then precipitated by addition of sodium acetate (pH 6.5, about 0.3 M) and
0.8 volumes
of 2-propanol. The DNA containing pellet is resuspended in Tris-EDTA buffer
and stored
at -20°C until use. Agarose gel electrophoresis shows a single band of
purified DNA.
[0079] M13 forward primers complementary to the known pBluescript~ sequence,
located next to the genomic DNA insert, are purchased from Midland Certified
Reagent
Company (Midland, TX). The primers are covalently modified to contain a biotin
moiety
attached to the 5' end of the oligonucleotide. The biotin group is covalently
linked to the
5'-phosphate of the primer via a (CH2)6 spacer. Biotin-labeled primers are
allowed to
hybridize to the ssDNA template molecules prepared from the pBluescript~
vector. The
primer-template complexes are then attached to streptavidine coated beads 14
according to
Dorre et al. (Bioimaging S: 139-152, 1997). At appropriate DNA dilutions, a
single
primer-template complex is attached to a single bead 14. A bead 14 containing
a single
primer-template complex is inserted into the r eaction chamber 11, 220 o f a
sequencing
apparatus 10, 100, 210.
[0080] The p rimer-template i s i ncubated w ith m odified T7 D NA p olymerase
( United
States Biochemical Corp., Cleveland, OH). The reaction mixture contains
unlabeled
deoxyadenosine-5'-triphosphate (dATP) and deoxyguanosine-5'-triphosphate
(dGTP),
digoxigenin-labeled deoxyuridine-5'-triphosphate (digoxigenin-dUTP) and
rhodamine-
labeled deoxycytidine-5'-triphosphate (rhodamine-dCTP). The polymerization
reaction is
allowed to proceed for 2 hours at 37°C. After synthesis of the
digoxigenin and rhodamine
labeled nucleic acid 13, the template strand is separated from the labeled
nucleic acid 13,
and the template strand, DNA polymerise and unincorporated nucleotides are
washed out
of the reaction chamber 11, 220.
CA 02478881 2004-09-09
WO 03/078649 PCT/US03/07641
[0081] Exonuclease 15 activity is initiated by addition of exonuclease III 15
to the
reaction chamber 11, 220. The reaction mixture is maintained at pH 8.0 and
37°C. As
nucleotides 16, 130 are released from the 3' end 17 of the nucleic acid 13,
they are
transported by microfluidic flow down the flow path 12 past the detection unit
18, 180,
300.
I~etectiovc ofLabeled Nucleotides
[0082] The detection unit 18, 180, 300 comprises a laser 19, 320 and Raman
detector
21, 310. The excitation beam 20, 330 is generated by a titaniumaapphire laser
19, 320
(Tsunami by Spectra-Physics) at a near-infrared wavelength (750950 nm) or a g
alium
aluminum arsenide diode laser 19, 320 (PI-ECL series by Process Instruments)
at 785 nm
or 830 nm. Pulsed laser beams 20, 330 or continuous beams 20, 330 can be used.
The
excitation beam 20, 330 is reflected by a dichroic mirror (holographic notch
filter by
Kaiser Optical or an interference filter by Chroma or Omega Optical) into a
collinear
geometry with the collected beam. The reflected beam passes a microscope
objective
(Nikon LU series), and is focused onto a micro-well, flow path (micro-channel)
12 or
flow-through cell 170, 290 where target nucleotides 16, 130 are located. The
Raman
scattered light from the t arget nucleotides 16, 130 is collected by the same
microscope
objective, and passes the dichroic mirror to the Raman detector 21, 310. The
Raman
detector 21, 310 comprises a focusing lens, a spectrograph, and an array
detector. The
focusing lens focuses the Raman scattered light through the entrance slit of
the
spectrograph. The spectrograph (RoperScientific) comprises a grating that
disperses the
light by its wavelength. The dispersed light is imaged onto an array detector
(back
illuminated deep-depletion CCD camera by RoperScientific). The array detector
is
connected to a controller circuit, which is connected to a computer for data
transfer and
control of the detector 21, 310 function.
[0083] The Raman detector 21, 310 is capable of detecting and identifying
single
nucleotides 16, 130 of dATP, dGTP, rhodamine-dCTP and digoxigenin-dUTP moving
past the detector 21, 310. Data on the time course for labeled nucleotide
detection is
compiled and analyzed to obtain the sequence of the nucleic acid 13.
Example 2: Nucleic Acid Sequencing Using Covalent Attachment to Nanoparticles
26
CA 02478881 2004-09-09
WO 03/078649 PCT/US03/07641
[0084] Another exemplary embodiment of the invention is disclosed in FIG. 2.
Nucleotides 16, 130 are released from a nucleic acid 13 by exonuclease 15
activity. In
certain embodiments of the invention, the nucleotides 16, 130 are unlabeled.
Such
embodiments do not involve incorporation of labeled nucleotides into a
complementary
strand 13 using primers and polymerases. Rather, nucleic acids 13 directly
purified from
any organ, tissue andlor cell sample or obtained by known cloning methods may
be
directly sequenced. In some embodiments of the invention, a single molecule of
single-
stranded RNA or DNA 13 may be attached to a surface 14 and treated with an
exonuclease
15. Released nucleotides 16, 130 travel down a flow path 12. The flow path 12
may be
contiguous with or identical to a microfluidic channel 110, 160, 260, 280.
[0085] Nucleotides 16, 130 from the reaction chamber 11, 220 are mixed with
gold
and/or silver nanoparticles 140. Silver nanoparticles 140 are prepared
according to Lee
and Meisel (J. Phys. Chem. 86:3391-3395, 1982). Gold nanoparticles 140 are
purchased
from Polysciences, Inc. (Warrington, PA). Gold nanoparticles 140 are available
from
Polysciences, Inc. in 5, 10, 15, 20, 40 and 60 nm sizes. In the present non-
limiting
Example, 60 nm gold nanoparticles 140 are used.
[0086] Prior to exposure to nucleotides 16, 130, surface-modified
nanoparticles 140 are
coated with a silane, such as 3-glycidoxypropyltrimethoxysilane (GOP), a
reactive linker
compound. GOP contains a terminal highly reactive epoxide group. Nanoparticles
140
may be modified to contain hydroxyl groups to allow covalent attachment of
GOP. The
silanized nanoparticles 140 are mixed with nucleotides 16, 130 and allowed to
form
covalent cross-links with the nucleotides 16, 130. The nucleotide-nanoparticle
complexes
150 pass through a flow through cell 170, 290 and are identified by SERS,
SERRS and/or
CARS using a Raman detection unit 18, 180, 300. Because of the close proximity
of the
nucleotides 16, 130 to the nanoparticles 140, the Raman signals are greatly
enhanced,
allowing detection of single nucleotides 16, 130 passing through the flow-
through cell
170, 290.
Example 3a Apparatus for Nucleic Acid Sequencing
[0087] FIG. 3 shows another exemplary embodiment of the invention. A DNA
sequencing apparatus 10, 100, 210 comprises a reaction chamber 11, 220 in
fluid
communication with an influx channel 230 and an efflux channel 240. Fluid
movement
27
CA 02478881 2004-09-09
WO 03/078649 PCT/US03/07641
may be controlled through the use of one or more valves 250. A microfluidic
channel 130,
260 is also in fluid communication with the reaction chamber 11, 220.
Nucleotides 16,
130 released from one or more nucleic acids 13 by exonuclease 15 activity exit
the
reaction chamber 11, 220 through the microfluidic channel 110, 260. The
nucleotides 16,
130 are mixed with nanoparticles 140 that move through a nanoparticle channel
120, 270
in fluid communication with the microfluidic channel 110, 260. Covalent
attachment of
nucleotides 16, 130 to nanoparticles 140 occurs within an attachment channel
160, 280.
The covalently bound nucleotide-nanoparticle complexes 150 pass through a flow-
through
cell 170, 290 where the nucleotides 16, 130 are identified by a Raman
detection unit 18,
180, 300. The detection unit 18, 180, 300 comprises a laser 19, 320 and Raman
detector
21, 310. The laser emits an excitation beam 20, 330 that excites nucleotides
16, 130
within the flow-through cell 170, 290. Excited nucleotides 16, 130 emit a
Raman signal
that is detected by the Raman detector 21, 310.
[0088] In certain embodiments of the invention, nanoparticles 140 may be
recovered in
a recycling chamber 340. The nanoparticles are chemically treated, for example
with acid
solutions, and then washed to remove bound nucleotides 16, 130, linker
compounds and
any other attached or adsorbed molecules. The nanoparticles 140 may be
recycled to a
nanoparticle reservoir 370 via a recycling channel 360. In some embodiments of
the
invention, nanoparticles 140 may be coated with a linker compound, such as
GOP, in the
recycling channel 360 and/or the nanoparticle reservoir 370. Waste effluent is
removed
from the recycling chamber 340 via a waste channel 350.
[0089] All of the METHODS and APPARATUS disclosed and claimed herein can be
made and executed without undue experimentation in light of the present
disclosure. It
will be apparent to those of skill in the art that variations may be applied
to the
METHODS and APPARATUS described herein without departing from the concept,
spirit
and scope of the claimed subject matter. More specifically, it will be
apparent that certain
agents that are both chemically and physiologically related may be substituted
for the
agents described herein w bile the same or similar results would be a chieved.
All such
similar substitutes and modifications apparent to those skilled in the art are
deemed to be
, within the spirit, scope and concept of the claimed subject matter.
28
